SCHEMBL20889072

SCHEMBL20889072

COc1cc(C(N)=O)cc(N)c1NC/C=C/CNC(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STING1 Q86WV6 6/20 0.45
KDM4E B2RXH2 1/20 0.38
CYP3A4 P08684 1/20 0.36
HTT P42858 2/20 0.34
TSHR P16473 1/20 0.34
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
ALDH1A1 P00352 3/20 0.34
LMNA P02545 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
BPTF Q12830 1/20 0.34
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33
TUBB4B P68371 1/20 0.33
TUBB3 Q13509 1/20 0.33
TUBB2A Q13885 1/20 0.33
TUBB8 Q3ZCM7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29406354 1.00 STING1 (0.45) STING1KDM4ECYP3A4HTTTSHR
SCHEMBL29012734 1.00 STING1 (0.45) STING1KDM4ECYP3A4HTTTSHR
SCHEMBL29080502 0.91 STING1 (0.38) STING1KDM4EHTTTSHRALDH1A1
SCHEMBL22313218 0.91 STING1 (0.38) STING1KDM4EHTTTSHRALDH1A1
SCHEMBL28453154 0.91 STING1 (0.38) STING1KDM4EHTTALDH1A1LMNA
SCHEMBL28453150 0.91 STING1 (0.38) STING1KDM4EHTTALDH1A1LMNA
SCHEMBL25098877 0.89 STING1 (0.46) STING1CYP3A4DRD2
SCHEMBL29868394 0.89 STING1 (0.46) STING1CYP3A4DRD2
SCHEMBL23077453 0.88 STING1 (0.40) STING1CYP3A4
SCHEMBL20889054 0.87 STING1 (0.44) STING1KDM4ECYP3A4HTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117794583-A Bisbenzimidazole STING agonist immunoconjugates and uses thereof 博尔特生物治疗药物有限公司 2024-03-29 CN disclosed
WO-2023215740-A1 IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES SEAGEN INC. (US) 2023-11-09 WO disclosed
CN-111417630-B Modulators of interferon gene stimulating factor (STING) 葛兰素史克知识产权开发有限公司 2023-06-06 CN disclosed
US-11377440-B2 Modulators of stimulator of interferon genes (STING) GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-07-05 US disclosed
EP-4006024-A1 HETEROCYCLIC AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) 2022-06-01 EP disclosed
US-11155567-B2 Sting agonist compounds and methods of use MERSANA THERAPEUTICS, INC. (US) 2021-10-26 US disclosed
US-10975287-B2 Heterocyclic amides useful as protein modulators GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 2021-04-13 US disclosed
US-20210032269-A1 STING AGONIST COMPOUNDS AND METHODS OF USE MERSANA THERAPEUTICS, INC. 2021-02-04 US disclosed
WO-2021013250-A1 HETEROCYCLIC AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 上海济煜医药科技有限公司 2021-01-28 WO disclosed
US-20200325126-A1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-10-15 US disclosed
US-20200291001-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-09-17 US disclosed
WO-2020156363-A1 IMMUNOMODULATOR 成都先导药物开发股份有限公司 2020-08-06 WO disclosed
CN-111417630-A Modulators of interferon gene stimulating factor (STING) 葛兰素史克知识产权开发有限公司 2020-07-14 CN disclosed
WO-2019134705-A1 IMMUNOMODULATOR 成都先导药物开发股份有限公司 2019-07-11 WO disclosed
WO-2019069270-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155567-B2 Sting agonist compounds and methods of use STING1, IRF3, MAVS STING1 1/4885KDM4E 3706/4885CYP3A4 4415/4885
US-20200325126-A1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS ARGLU1, G3BP1, G3BP2 STING1 2510/4885KDM4E 2147/4885CYP3A4 3885/4885
US-11377440-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, IFNAR1 STING1 1/4885KDM4E 3402/4885CYP3A4 3948/4885
US-10975287-B2 Heterocyclic amides useful as protein modulators ARGLU1, G3BP1, G3BP2 STING1 2510/4885KDM4E 2147/4885CYP3A4 3885/4885
US-20210032269-A1 STING AGONIST COMPOUNDS AND METHODS OF USE STING1, IRF3, MAVS STING1 1/4885KDM4E 3706/4885CYP3A4 4415/4885
US-20200291001-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, IFNAR1 STING1 1/4885KDM4E 3402/4885CYP3A4 3948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.